PRTA Live signaler | Maksimer profitt med Getagraph.com

KJøP 113484 min ago

@ $27.01

Utstedt: 14 feb 2024 @ 21:42

Avkastning: -13.99%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: -1.57 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 18:06):

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States...

Stats
Dagens volum	193 587
Gjennomsnittsvolum	626 303
Markedsverdi	1.25B
EPS	$0 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.42
ATR14	$0.0210 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Ford David A	Buy	85 000	Stock Option (Right to Buy)
2024-03-01	Ford David A	Buy	0
2024-02-27	Zago Wagner M.	Buy	85 000	Stock Option (Right to Buy)
2024-02-27	Walker Karin L	Buy	54 000	Stock Option (Right to Buy)
2024-02-27	Smith Brandon S.	Buy	85 000	Stock Option (Right to Buy)

INSIDER POWER
77.74
Last 98 transactions
Buy: 1 184 000 \| Sell: 192 000

Volum Korrelasjon

Lang: 0.20 (neutral)

Kort: 0.00 (neutral)

Signal:(45.759) Neutral

Prothena Corporation PLC Korrelasjon

10 Mest positive korrelasjoner
TSLA	0.958
ASTS	0.942
AEHR	0.941
OM	0.939
WW	0.937
ZLAB	0.937
MSEX	0.936
ASLE	0.936
FWRD	0.935
IDBA	0.934

10 Mest negative korrelasjoner
KVSC	-0.96
BCOR	-0.952
MCAA	-0.94
HCNE	-0.939
BHAC	-0.938
APXI	-0.937
FTIV	-0.936
VMGA	-0.935
RNLC	-0.935
GEEX	-0.934

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Prothena Corporation PLC Korrelasjon - Valuta/Råvare

-0.55
( weak negative )

-0.59
( weak negative )

0.00
( neutral )

-0.46
( neutral )

-0.48
( neutral )

0.23
( neutral )

Prothena Corporation PLC Økonomi

Annual	2023
Omsetning:	$91.37M
Bruttogevinst:	$82.96M (90.79 %)
EPS:	$-2.76

FY	2023
Omsetning:	$91.37M
Bruttogevinst:	$82.96M (90.79 %)
EPS:	$-2.76

FY	2022
Omsetning:	$53.91M
Bruttogevinst:	$47.16M (87.49 %)
EPS:	$-2.47

FY	2021
Omsetning:	$200.58M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$1.510

Financial Reports:

No articles found.

Prothena Corporation PLC

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.